{"id":"nasal-diazepam","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Ataxia"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL12","moleculeType":"Small molecule","molecularWeight":"284.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diazepam binds to benzodiazepine receptors on GABA-A receptors, potentiating the effect of the inhibitory neurotransmitter GABA. This results in sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. The intranasal formulation provides rapid onset of action, bypassing first-pass hepatic metabolism and enabling faster CNS penetration compared to oral administration.","oneSentence":"Nasal diazepam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system when administered intranasally.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:39.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute seizure management and seizure cluster treatment"},{"name":"Acute anxiety and agitation"}]},"trialDetails":[{"nctId":"NCT06346262","phase":"PHASE4","title":"Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2024-03-05","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT07020988","phase":"PHASE1","title":"A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2025-06-12","conditions":"Healthy Participants","enrollment":55},{"nctId":"NCT05076838","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy","status":"COMPLETED","sponsor":"Neurelis, Inc.","startDate":"2021-11-08","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT05273398","phase":"PHASE4","title":"Effects of Diazepam on RNS Detections","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2022-03-01","conditions":"Epilepsies, Partial","enrollment":4},{"nctId":"NCT02784262","phase":"PHASE2","title":"Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-10","conditions":"Chronic Disease, Nasal Polyposis, Rhinitis","enrollment":11},{"nctId":"NCT01364558","phase":"PHASE1","title":"A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2011-02","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT02474407","phase":"PHASE2","title":"Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)","status":"TERMINATED","sponsor":"Acorda Therapeutics","startDate":"2015-06","conditions":"Refractory Epilepsy","enrollment":78},{"nctId":"NCT02316847","phase":"PHASE2","title":"An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.","status":"TERMINATED","sponsor":"Acorda Therapeutics","startDate":"2014-12","conditions":"Epilepsy","enrollment":126},{"nctId":"NCT01417078","phase":"PHASE2","title":"A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2011-09","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT02663999","phase":"PHASE1","title":"A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2016-01","conditions":"Healthy","enrollment":15},{"nctId":"NCT02313337","phase":"PHASE4","title":"The Comparison of Different Administration Routes of Pediatric Premedication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2014-12","conditions":"Anesthesia","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":193,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nasal diazepam (Valtoco)"],"phase":"marketed","status":"active","brandName":"nasal diazepam","genericName":"nasal diazepam","companyName":"University of Cincinnati","companyId":"university-of-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nasal diazepam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system when administered intranasally. Used for Acute seizure management and seizure cluster treatment, Acute anxiety and agitation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}